The U.S. Centers for Disease Control and Prevention announced Tuesday that the Advisory Community on Immunization Practices will meet on Aug. 3 to determine recommendations for Beyfortus, a new treatment for respiratory syncytial virus, or RSV. The ACIP is a governing body that informs the CDC director on immunization policies such as scheduling, insurance coverage and cost of the treatment.
The announcement comes one day after the Food and Drug Administration announced that Beyfortus, generic name nirsevimab, had been approved to prevent RSV in infants and high-risk toddlers, with supply slated to hit doctors’ offices this fall. The ACIP meeting will advise the timing of the rollout to the public, as well as determine whether the new treatment will be included as part of the CDC’s Vaccines for Children, a federally funded program offering free vaccines and treatments to kids who may not otherwise receive them due to cost barriers.
Beyfortus is a collaboration between the biotech companies AstraZeneca and Sanofi.
A virus affecting the lower respiratory tract, RSV is the leading cause of hospitalization in infants under the age of 1. It can impact people of all ages. Last winter saw a surge in cases in the region and nationally, which led to what experts dubbed a “tripledemic” — of influenza, COVID-19 and RSV — as patients filled hospitals, leading to hours-long wait times.
Dr. Joe Aracri, chair of Allegheny Health Network Pediatrics, said half of all RSV hospitalizations nationwide were newborns with no pre-existing conditions.
The CDC has estimated that RSV, in children under 5 years old, leads to 58,000to 80,000 hospitalizations and 100 to 300 deaths annually. The virus also leads to about 6,000 to 10,000 deaths among adults 65 and older per year. In May, the FDA approved RSV vaccine Arexvy for adults over 60, developed by GlaxoSmithKline. The FDA has also previously approved an RSV treatment for pregnant mothers to transfer antibodies to their babies, as well as palivizumab, under the brand name Synagis, as a five-dose RSV treatment for high-risk babies.
“Beyfortus is the only monoclonal antibody approved for passive immunization to provide safe and effective protection for all infants during their first RSV season,” said Sanofi executive vice president of vaccines Thomas Triomphe in a Tuesday news release from the company. “I am proud that, by prioritizing this potential game-changer, we are now about to bring Beyfortus to American families.”
Beyfortus is a monoclonal antibody given prophylactically to prevent RSV in infants and high-risk toddlers. Administered via injection, the technology is not a vaccine because it does not stimulate an infant’s immune system, but provides the antibody directly to the body, giving what is called passive immunization.
An FDA advisory committee voted unanimously to recommend Beyfortus for infants under 1, and it voted 19 to 2 in support for high-risk toddlers under 2 to receive the treatment.
“RSV is a very common ... community-acquired respiratory virus that has a propensity to cause important illness in the very young and very old,” said Dr. Michael Green, medical director for infection prevention at UPMC Children’s Hospital and a pediatric infectious disease physician. “The information I have seen about this product is that it will decrease the number of medically attended visits. ... This could really have an impact on the health of babies and keep them out of [intensive care units].”
A Sanofi spokesperson said the company expects the product to be given by hospital staff when a baby is born or by a primary care provider, and that the company supports adding the drug to the Vaccines for Children program.
“As every infant is at risk from RSV, we believe all babies deserve equal access to RSV protection,” said the spokesperson in an email statement. “Key to being able to offer protection for all infants is our work with the ACIP to evaluate Beyfortus for placement on the childhood immunization schedule, as the Affordable Care Act (ACA) generally requires insurance coverage for all immunizations administered in accordance with final CDC recommendations.”
According to clinical trials, nirsevimab reduced the risk of RSV in 70% of cases for preterm babies entering their first RSV season and 75% for healthy babies born at or later than 35 weeks. Side effects appeared mild, with some risk of skin rashes.
Dr. Aracri said these numbers were promising because healthy babies historically have had zero protection against RSV. “This therapy is very exciting for pediatricians,” he said. “This is going to be another one of those game-changers that will really help these little babies.”
The treatment is approved for one dose that lasts the length of RSV season, or about 5 months. A child born in September or October could get the dose at the hospital when they are born, just before the season, and a child born in March or April is advised to wait until just before the next RSV season.
“Not only can this save hospitalizations, but it can save lives,” said Dr. Green.
Hanna Webster: hwebster@post-gazette.com






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.